<bill session="116" type="h" number="1503" updated="2022-11-01T17:03:26Z">
  <state datetime="2021-01-05">ENACTED:SIGNED</state>
  <status>
    <unknown datetime="2021-01-05"/>
  </status>
  <introduced datetime="2019-03-05"/>
  <titles>
    <title type="display">Orange Book Transparency Act of 2020</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act regarding the list under section 505(j)(7) of the Federal Food, Drug, and Cosmetic Act, and for other purposes.</title>
    <title type="short" as="reported to house">Orange Book Transparency Act of 2019</title>
    <title type="short" as="introduced">Orange Book Transparency Act of 2019</title>
    <title type="short" as="enacted">Orange Book Transparency Act of 2020</title>
    <title type="short" as="passed senate">Orange Book Transparency Act of 2020</title>
    <title type="short">Orange Book Transparency Act of 2020</title>
    <title type="short" as="passed house">Orange Book Transparency Act of 2019</title>
    <title type="short" as="passed house">Orange Book Transparency Act of 2019</title>
  </titles>
  <sponsor bioguide_id="K000385"/>
  <cosponsors>
    <cosponsor bioguide_id="C001067" joined="2019-04-04"/>
    <cosponsor bioguide_id="C001119" joined="2019-04-02"/>
    <cosponsor bioguide_id="D000624" joined="2019-04-02"/>
    <cosponsor bioguide_id="E000215" joined="2019-04-02"/>
    <cosponsor bioguide_id="K000379" joined="2019-04-02"/>
    <cosponsor bioguide_id="M001163" joined="2019-04-02"/>
    <cosponsor bioguide_id="M001207" joined="2019-05-01"/>
    <cosponsor bioguide_id="P000034" joined="2019-04-02"/>
    <cosponsor bioguide_id="R000599" joined="2019-04-02"/>
    <cosponsor bioguide_id="R000515" joined="2019-04-02"/>
    <cosponsor bioguide_id="S001145" joined="2019-04-12"/>
    <cosponsor bioguide_id="V000133" joined="2019-04-04"/>
    <cosponsor bioguide_id="W000791" joined="2019-04-04"/>
  </cosponsors>
  <actions>
    <action datetime="2019-03-05">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-03-05" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2019-03-06">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
    <action datetime="2019-03-27">
      <text>Subcommittee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-03-27">
      <text>Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .</text>
    </action>
    <action datetime="2019-04-03">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2019-04-03" state="REPORTED">
      <text>Ordered to be Reported (Amended) by Voice Vote.</text>
    </action>
    <action datetime="2019-05-02">
      <text>Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-47.</text>
    </action>
    <calendar datetime="2019-05-02" calendar="Union" number="25">
      <text>Placed on the Union Calendar, Calendar No. 25.</text>
    </calendar>
    <action datetime="2019-05-08T12:25:20-04:00">
      <text>Ms. Eshoo moved to suspend the rules and pass the bill, as amended.</text>
    </action>
    <action datetime="2019-05-08T12:25:45-04:00">
      <text>Considered under suspension of the rules.</text>
      <reference ref="CR H3486-3488" label="consideration"/>
    </action>
    <action datetime="2019-05-08T12:25:47-04:00">
      <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 1503.</text>
    </action>
    <action datetime="2019-05-08T12:36:19-04:00">
      <text>At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.</text>
    </action>
    <action datetime="2019-05-08T13:31:33-04:00">
      <text>Considered as unfinished business.</text>
      <reference ref="CR H3491" label="consideration"/>
    </action>
    <vote how="roll" type="vote" roll="187" datetime="2019-05-08T13:59:34-04:00" where="h" result="pass" suspension="1" state="PASS_OVER:HOUSE">
      <text>On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 422 - 0 (Roll no. 187).</text>
      <reference ref="CR H3486-3487" label="text"/>
    </vote>
    <action datetime="2019-05-08T13:59:35-04:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <action datetime="2019-05-09">
      <text>Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
    <action datetime="2020-12-07">
      <text>Measure laid before Senate by unanimous consent.</text>
      <reference ref="CR S7244" label="consideration"/>
    </action>
    <action datetime="2020-12-07">
      <text>Senate Committee on Health, Education, Labor, and Pensions discharged by Unanimous Consent.</text>
    </action>
    <vote how="by Unanimous Consent" type="vote2" datetime="2020-12-07" where="s" result="pass" state="PASS_BACK:SENATE">
      <text>Passed Senate with an amendment by Unanimous Consent.</text>
      <reference ref="CR S7242-7243" label="text of amendment in the nature of a substitute"/>
    </vote>
    <action datetime="2020-12-08">
      <text>Message on Senate action sent to the House.</text>
    </action>
    <action datetime="2020-12-10T12:12:00-05:00">
      <text>Mrs. Dingell asked unanimous consent that the House agree to the Senate amendment.</text>
    </action>
    <action datetime="2020-12-10T12:12:01-05:00">
      <text>Mrs. Dingell asked unanimous consent to take the bill, H.R. 1503 from the Speaker's Table and agree to the Senate amendment.</text>
      <reference ref="CR H7130-7131" label="consideration"/>
    </action>
    <vote how="without objection" type="pingpong" datetime="2020-12-10T12:12:38-05:00" where="h" result="pass" state="PASSED:BILL">
      <text>On motion that the House agree to the Senate amendment Agreed to without objection.</text>
      <reference ref="CR H7130-7131" label="text"/>
    </vote>
    <action datetime="2020-12-10T12:12:39-05:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <topresident datetime="2020-12-24">
      <text>Presented to President.</text>
    </topresident>
    <signed datetime="2021-01-05" state="ENACTED:SIGNED">
      <text>Signed by President.</text>
    </signed>
    <enacted number="116-290" type="public" datetime="2021-01-05">
      <text>Became Public Law No: 116-290.</text>
    </enacted>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Discharged, Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Reporting, Markup, Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Reporting, Markup, Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="19" relation="unknown"/>
    <bill session="116" type="h" number="1503" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Congressional oversight"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Food and Drug Administration (FDA)"/>
    <term name="Government information and archives"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments>
    <amendment number="s2693"/>
  </amendments>
  <summary date="2021-09-12T15:36:40Z" status="Public Law">Orange Book Transparency Act of 2020

This bill modifies requirements for the Food and Drug Administration (FDA)to list and publish drug patent and exclusivity information. Specifically, the FDA must include on its list certain patent information and must specify each drug exclusivity period that has not concluded. The holder of an approved drug application must notify the FDA when a listed patent is invalidated by a court or by the Patent Trial and Appeal Board. The FDA must remove invalidated patents from its list, subject to the 180-day drug exclusivity period.</summary>
  <committee-reports>
    <report>H. Rept. 116-47</report>
  </committee-reports>
</bill>
